Seven Epidemic Waves of COVID-19 in a Hospital in Madrid: Analysis of Severity and Associated Factors

(1) Background: COVID-19 has evolved during seven epidemic waves in Spain. Our objective was to describe changes in mortality and severity in our hospitalized patients. (2) Method: This study employed a descriptive, retrospective approach for COVID-19 patients admitted to the Hospital de Fuenlabrada (Madrid, Spain) until 31 December 2022. (3) Results: A total of 5510 admissions for COVID-19 were recorded. The first wave accounted for 1823 (33%) admissions and exhibited the highest proportion of severe patients: 65% with bilateral pneumonia and 83% with oxygen saturation under 94% during admission and elevated levels of CRP, IL-6, and D-dimer. In contrast, the seventh wave had the highest median age (79 years) and comorbidity (Charlson: 2.7), while only 3% of patients had bilateral pneumonia and 3% required intubation. The overall mortality rate was 10.3%. The first wave represented 39% of the total. The variables related to mortality were age (OR: 1.08, 1.07–1.09), cancer (OR: 1.99, 1.53–2.60), dementia (OR: 1.82, 1.20–2.75), the Charlson index (1.38, 1.31–1.47), the need for high-flow oxygen (OR: 6.10, 4.94–7.52), mechanical ventilation (OR: 11.554, 6.996–19.080), and CRP (OR: 1.04, 1.03–1.06). (4) Conclusions: The variables associated with mortality included age, comorbidity, respiratory failure, and inflammation. Differences in the baseline characteristics of admitted patients explained the differences in mortality in each wave. Differences observed between patients admitted in the latest wave and the earlier ones suggest that COVID-19 has evolved into a distinct disease, requiring a distinct approach.

[1]  Zahra Heydarifard,et al.  Comparison of clinical outcomes, demographic, and laboratory characteristics of hospitalized COVID‐19 patients during major three waves driven by Alpha, Delta, and Omicron variants in Tehran, Iran , 2023, Influenza and Other Respiratory Viruses.

[2]  M. A. Haque,et al.  Difference in presentation, outcomes, and hospital epidemiologic trend of COVID-19 among first, second, and third waves: a review of hospital records and prospective cohort study , 2023, Annals of Medicine and Surgery.

[3]  J. Marshall,et al.  Outcomes and characteristics of patients hospitalized for COVID-19 in British Columbia, Ontario and Quebec during the Omicron wave , 2023, CMAJ open.

[4]  R. Gil-Prieto,et al.  Differences in Trends in Admissions and Outcomes among Patients from a Secondary Hospital in Madrid during the COVID-19 Pandemic: A Hospital-Based Epidemiological Analysis (2020–2022) , 2023, Viruses.

[5]  J. Ramos-Rincón,et al.  Improving prediction of COVID-19 mortality using machine learning in the Spanish SEMI-COVID-19 registry , 2023, Internal and Emergency Medicine.

[6]  B. D'avanzo,et al.  Two years of SARS-CoV-2 pandemic and COVID-19 in Lombardy, Italy , 2023, Internal and Emergency Medicine.

[7]  Guangdi Li,et al.  Therapeutic strategies for COVID-19: progress and lessons learned , 2023, Nature Reviews Drug Discovery.

[8]  Y. Coppieters,et al.  Caractéristiques épidémiologiques de l’épidémie de Covid-19 entre 2020 et 2022 au Kongo central, RDC , 2023, Medecine tropicale et sante internationale.

[9]  J. Haughney,et al.  The SARS-CoV-2 Alpha variant was associated with increased clinical severity of COVID-19 in Scotland: A genomics-based retrospective cohort analysis , 2023, PloS one.

[10]  Y. Okada,et al.  Characteristics and clinical effectiveness of COVID-19 vaccination in hospitalized patients in Omicron-dominated epidemic wave – a nationwide study in Japan , 2023, International Journal of Infectious Diseases.

[11]  L. Danon,et al.  Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: A prospective cohort study in Bristol, United Kingdom , 2022, The Lancet Regional Health - Europe.

[12]  M. Kanai,et al.  Characteristics of hospitalized patients with COVID-19 during the first to fifth waves of infection: a report from the Japan COVID-19 Task Force , 2022, BMC infectious diseases.

[13]  Jonathan E. Suk,et al.  Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe , 2022, European Respiratory Review.

[14]  Jorge A. Marrero,et al.  Comparative Study of Vaccinated and Unvaccinated Hospitalised Patients: A Retrospective Population Study of 500 Hospitalised Patients with SARS-CoV-2 Infection in a Spanish Population of 220,000 Inhabitants , 2022, Viruses.

[15]  J. Ramos-Rincón,et al.  Differences in clinical features and mortality in very old unvaccinated patients (≥ 80 years) hospitalized with COVID-19 during the first and successive waves from the multicenter SEMI-COVID-19 Registry (Spain) , 2022, BMC Geriatrics.

[16]  M. Faccini,et al.  A Comparison Between Omicron and Earlier COVID-19 Variants' Disease Severity in the Milan Area, Italy , 2022, Frontiers in Epidemiology.

[17]  M. Clèries,et al.  Is Age the Most Important Risk Factor in COVID-19 Patients? The Relevance of Comorbidity Burden: A Retrospective Analysis of 10,551 Hospitalizations , 2022, medRxiv.

[18]  W. Haas,et al.  SARS-CoV-2 Omicron variants BA.1 and BA.2 both show similarly reduced disease severity of COVID-19 compared to Delta, Germany, 2021 to 2022 , 2022, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[19]  Brett K. Beaulieu-Jones,et al.  Changes in laboratory value improvement and mortality rates over the course of the pandemic: an international retrospective cohort study of hospitalised patients infected with SARS-CoV-2 , 2022, BMJ Open.

[20]  J. Tesoriero,et al.  Factors associated with SARS-CoV-2-related hospital outcomes among and between persons living with and without diagnosed HIV infection in New York State , 2022, PloS one.

[21]  Colin Simpson,et al.  Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design , 2022, The Lancet Infectious Diseases.

[22]  H. Ullum,et al.  Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study , 2022, The Lancet Infectious Diseases.

[23]  H. Jacquier,et al.  Comparison of Patients Infected With Delta Versus Omicron COVID-19 Variants Presenting to Paris Emergency Departments , 2022, Annals of Internal Medicine.

[24]  R. Kohli-Seth,et al.  The Third Wave: Comparing Seasonal Trends in COVID-19 Patient Data at a Large Hospital System in New York City , 2022, Critical Care Explorations.

[25]  P. Noble,et al.  Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance — One Hospital, California, July 15–September 23, 2021, and December 21, 2021–January 27, 2022 , 2022, MMWR. Morbidity and mortality weekly report.

[26]  M. Mendelson,et al.  Outcomes of laboratory‐confirmed SARS‐CoV‐2 infection in the Omicron‐driven fourth wave compared with previous waves in the Western Cape Province, South Africa , 2022, medRxiv.

[27]  O. Sued,et al.  Clinical characteristics and outcomes of hospitalized patients with SARS-CoV-2 infection in a Latin American country: Results from the ECCOVID multicenter prospective study , 2021, PloS one.

[28]  G. Poudel,et al.  Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection , 2021, JAMA network open.

[29]  V. Soriano,et al.  Impact of scaling up SARS-CoV-2 vaccination on COVID-19 hospitalizations in Spain , 2021, International Journal of Infectious Diseases.

[30]  I. Toprak,et al.  Comparison of demographic and clinical characteristics of hospitalized COVID‐19 patients with severe/critical illness in the first wave versus the second wave , 2021, Journal of medical virology.

[31]  Jeffrey G. Klann,et al.  International Changes in COVID-19 Clinical Trajectories Across 315 Hospitals and 6 Countries: Retrospective Cohort Study , 2021, Journal of medical Internet research.

[32]  Joshua B. Singer,et al.  Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study , 2021, The Lancet Infectious Diseases.

[33]  E. Orenbuch-Harroch,et al.  BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel , 2021, Clinical Microbiology and Infection.

[34]  Colin Simpson,et al.  Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study , 2021, The Lancet.

[35]  R. Loomba,et al.  Serum biomarkers for prediction of mortality in patients with COVID-19 , 2021, Annals of clinical biochemistry.

[36]  J. Nkengasong,et al.  The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study , 2021, The Lancet.

[37]  Ana Macedo,et al.  COVID-19 fatality rates in hospitalized patients: systematic review and meta-analysis , 2021, Annals of Epidemiology.

[38]  Vaishali R. Moulton,et al.  Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections? , 2021, Frontiers in Physiology.

[39]  R. Schwartz,et al.  Characteristics and Outcomes of COVID-19 Patients During Initial Peak and Resurgence in the Houston Metropolitan Area. , 2020, JAMA.

[40]  J. Ramos-Rincón,et al.  Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Registry , 2020, Revista Clínica Española (English Edition).

[41]  Rodney P. Jones.  Would the United States Have Had Too Few Beds for Universal Emergency Care in the Event of a More Widespread Covid-19 Epidemic? , 2020, International journal of environmental research and public health.

[42]  M. Kabir,et al.  Comorbidities might be a risk factor for the incidence of COVID-19: Evidence from a web-based survey , 2020, Preventive Medicine Reports.

[43]  L. Nayak,et al.  The hypercoagulable state in COVID-19: Incidence, pathophysiology, and management , 2020, Thrombosis Research.

[44]  P. Horby,et al.  Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study , 2020, BMJ.

[45]  Leora I. Horwitz,et al.  Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study , 2020, BMJ.

[46]  M. Hernán,et al.  A Cohort of Patients with COVID-19 in a Major Teaching Hospital in Europe , 2020, medRxiv.

[47]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[48]  M. Mckenney,et al.  Social distancing during the COVID-19 pandemic: Staying home save lives , 2020, The American Journal of Emergency Medicine.

[49]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[50]  G. Gao,et al.  A Novel Coronavirus from Patients with Pneumonia in China, 2019 , 2020, The New England journal of medicine.